Vincerx Pharma, Inc. (NASDAQ:VINC) Short Interest Update

Vincerx Pharma, Inc. (NASDAQ:VINC) was the recipient of a large decrease in short interest in the month of December. As of December 15th, there was short interest totalling 419,600 shares, a decrease of 42.9% from the November 30th total of 735,400 shares. Based on an average daily volume of 702,800 shares, the days-to-cover ratio is currently 0.6 days.

Vincerx Pharma Price Performance

VINC stock opened at $0.18 on Friday. The company has a market cap of $6.19 million, a price-to-earnings ratio of -0.18 and a beta of 1.48. The company has a fifty day moving average price of $0.28 and a 200 day moving average price of $0.53. Vincerx Pharma has a 12 month low of $0.18 and a 12 month high of $9.37.

Institutional Investors Weigh In On Vincerx Pharma

A hedge fund recently raised its stake in Vincerx Pharma stock. Marshall Wace LLP boosted its stake in Vincerx Pharma, Inc. (NASDAQ:VINC) by 359.1% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 328,533 shares of the company’s stock after acquiring an additional 256,967 shares during the period. Marshall Wace LLP owned 1.11% of Vincerx Pharma worth $266,000 as of its most recent SEC filing. 44.02% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Leerink Partners cut their price target on Vincerx Pharma from $4.00 to $2.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th.

Vincerx Pharma Company Profile

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.